Serum cholesterol and triglycerides in Parkinson`s disease and essential tremor by Ivanov, Borislav et al.
Received 1 December 2015, revised 10 December 2015, accepted 18 December 2015. 
Correspondence to Dr Borislav Ivanov, MD, PhD, Department of Clinical Medical Sciences, Medical University and First 
Clinic of Neurology, University St Marina Hospital, Varna, Bulgaria. Tel.: 359 52 978524; E-mail: borislav.ivanov@mail.bg
© Bul garian Society for Cell Biology
ISSN 1314-1929 (online)
Biomedical Reviews 2015; 26: 43-46
SERUM CHOLESTEROL AND TRIGLYCERIDES IN PARKINSON’S DISEASE  
AND ESSENTIAL TREMOR
Borislav Ivanov1, Ara Kaprelyan2, Ivan Dimitrov3, Margarita Grudkova2, Natalia Usheva4, Vesselina 
Nestorova5, and Nadezhda Deleva2 
1Department of Clinical Medical Sciences, Medical University and First Clinic of Neurology,  
University St Marina Hospital, Varna, Bulgaria, Departmentof Neurology, Medical University, Varna, 
Bulgaria, Department 
of Social Medicine and Healthcare Organization, Medical University, Varna, Bulgaria, Department of 
Physiotherapy, Rehabilitation, Thalassotherapy, Occupational Diseases and Disaster Medicine,  
Medical University, Varna, Bulgaria
The role of lipid metabolism in the pathogenesis of Parkinson`s disease is still controversial. Most authors suggest that higher 
The role of lipid metabolism in the pathogenesis of Parkinson`s disease is still controversial. Most authors suggest that higher 
serum cholesterol may be associated with a lower risk of Parkinson`s disease. Debates exist as to whether essential tremor 
shares similar neuropathological mechanisms as Parkinson`s disease. We investigated serum total cholesterol and triglycer-
ide levels in a clinical setting of Parkinson`s disease versus essential tremor patients. Two hundred and sixteen Parkinson`s 
cholesterol and triglyceride in essential tremor patients. Results differ statistically only on gender level with increased cho-
Parkinson`s disease and essential tremor. Further research may elucidate the role of lipid metabolism changes in both diseases. 
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WE DANCE ROUND IN A RING AND SUPPOSE,
BUT THE SECRET SITS IN THE MIDDLE AND KNOWS.
ROBERT FROST
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INTRODUCTION
There are growing evidences that changes of lipid metabo-
lism are involved in the pathophysiology of neurodegenera-
tive diseases (1, 2) Several large prospective and population-
based studies have reported controversial results. Most authors 
suggest that higher serum cholesterol may be associated with 
lower risk of Parkinson`s disease (PD) (3). Meanwhile, it was 
shown that PD patients have lower cholesterol than controls 
(4). Debates exist as to whether essential tremor (ET) shares 
similar pathophysiological mechanisms with PD (5).
SUBJECTS AND METHODS
We investigated serum total cholesterol and triglycerides 
levels in a clinical setting of 216 PD patients (126 males, 
90 females), aged 68.0 ± 9.3 years (40-85 years), with 4.6 
± 3.9 years (1-20 years) disease duration, and 342 ET pa-
tients (118 males, 224 females), aged 69.4 ± 8.3 years (32-91 
years), with 5.3 ± 6.2 years (1-40 years) disease duration, as 
hospitalized in a 7-year period at First Clinic of Neurology, 
University St Marina Hospital Varna, Bulgaria.
RESULTS 
For the Parkinson`s disease group levels of serum total cho-
lesterol and triglycerides were as follow: 5.06 ± 1.17 mmol/l 
(2.5-8.94) and 1.29± 0.64 mmol/l (0.41-3.9) versus 5.33 ± 
1.14 mmol/l (2.17-9.8) and 1.53 ± 0.77 mmol/l (0.31-5.51) 
respectively for essential tremor patients. The laboratory’s 
-
values of serum total cholesterol and triglycerides in PD and 
ET groups are shown of Table 1.
for serum total cholesterol and females for triglycerides (Ta-
ble 2) with higher levels in the ET group.
Mean levels of serum total cholesterol for ET is higher 
than the laboratory norm (2.7-5.2 mmol/l), whereas serum 




Serum total cholesterol Triglyceride
PD 5.06±1.17 mmol/l (2.5-8.9) 1.29± 0.64 mmol/l (0.4-3.9)
ET 5.33± 1.14 mmol/l (2.2-9.8) 1.53±0.77 mmol/l (0.3-5.5)
Table 2. 



















*p=0.006 (Independent samples t- test)
**p=0.001(Independent samples t- test)
Table 3
Normal STCh and 3-gly Low STCh High STCh High 3-gly High STCh and 3-gly 
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DISCUSSION
Essential tremor is the most common movement disorder. 
The possible relationship between ET and PD has been de-
1817. There is increasing evidences suggesting an overlap 
between these two disorders (5). Cholesterol is vital for the 
neuronal functional and structural integrity. Brain cholesterol 
metabolism changes are linked to neurodegeneration (6). 
Data for lipids in ET are scarce. One study found increased 
levels of cholesterol in ET (7). Meanwhile several studies 
in PD obtained controversial results. Some authors suggest 
that higher serum total cholesterol may be associated with 
lower future risk of PD and slower disease progression, espe-
cially in females (8-10, 11), others found no association (12, 
13), and one large study suggested that elevated serum total 
cholesterol is linked to elevated PD risk in males under 55 
years of age (14). Most researchers agreed that serum total 
cholesterol and LDL in PD are lower as compared to controls 
(15). Recent Finnish study concluded that elevated serum tri-
glycerides predicted low PD incidence (16).
-
lesterol and triglycerides in our ET patients. Results differ sta-
tistically only on gender levels. Gender differences are debated 
regarding the role of sex hormones and lipid metabolism (12). 
In regard to laboratory referent level, mean serum total cho-
lesterol of ET patients is higher, supporting the results of (7). 
In vitro results suggested an association between cholesterol 
and localization and structure of alpha- synuclein, the essential 
protein component of Lewy bodies, pathological hallmark of 
PD. At the same time Lewy bodies were found in brainstems 
of 1/3 of autopsied ET cases. Moreover, cholesterol is the most 
important determinant of levels of coenzyme Q10, a powerful 
antioxidant and mitochondrial electron acceptor, involved in 
pathophysiology of neurodegenerative diseases (17, 18).
Essential tremor is no more considered benign, mono-
symptomatic disorder. Growing evidences in the last 10 years 
suggested that ET is rather a neurodegenerative disease. Re-




erides in the ET group may be discussed as a potential indica-
tor for divergent pathophysiological mechanisms underlying 
PD and ET. Further research may elucidate the role of lipid 
metabolism in both diseases.
interest.
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